COVID Clinical Trial
Official title:
Effect of SARS- COVID-19 Pandemic on Female Sexual Behavior
World Health Organization declared new SARS-CoV-2 infection a pandemic, and many states enacted strict, rules such as border closures, transportation restrictions and quarantine.Many studies in the literature have described the relationship between mass disasters and female sexual behavior, but none have investigated the effect of SARS-CoV-2 pandemic on women's sexual attitude. The aim of this study is therefore to evaluate the effect of SARS-CoV-2 pandemic on female sexual behavior.
Coronaviruses are a group of RNA viruses that affect mainly the respiratory system and cause
the common cold, fever, and coughs in mammals and birds. However, in some cases,
coronaviruses are associated with more serious and lethal conditions, such as pneumonia,
bronchitis, and severe acute respiratory syndrome. A novel coronavirus (SARS-CoV-2)
originating from Wuhan, China led to a global health crisis. At the time of writing,
SARS-CoV-2 infected more than two million, resulting in almost 180.000 deaths. World Health
Organization declared new SARS-CoV-2 infection a pandemic, and many states enacted strict,
rules such as border closures, transportation restrictions, and quarantine.
The term 'sexual behavior' encompasses a large spectrum of actions in which humans present
their sexuality. Previous reports have analyzed the effect of mass disasters on female sexual
behavior.
Many studies in the literature have described the relationship between mass disasters and
female sexual behavior, but none have investigated the effect of the SARS-CoV-2 pandemic on
women's sexual attitude. The aim of this study is therefore to evaluate the effect of the
SARS-CoV-2 pandemic on female sexual behavior.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
| Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04420676 -
Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection
|
N/A | |
| Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
| Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
| Completed |
NCT04425317 -
Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients
|
N/A | |
| Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
| Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
| Completed |
NCT04425720 -
Use of Remote Monitoring for COVID-19 Patient
|
N/A | |
| Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
| Completed |
NCT04419610 -
RAS and Coagulopathy in COVID19
|
Early Phase 1 | |
| Completed |
NCT04546581 -
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
|
Phase 3 | |
| Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
| Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
| Not yet recruiting |
NCT04524156 -
COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2
|
N/A | |
| Completed |
NCT04441710 -
Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
|
||
| Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
| Not yet recruiting |
NCT04392427 -
New Antiviral Drugs for Treatment of COVID-19
|
Phase 3 | |
| Terminated |
NCT04614025 -
Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
|
Phase 2 | |
| Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 |